Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S, Mareschal S, Picquenot JM, Viailly PJ, Bohers E, Cornic M, Bertrand P, Veresezan EL, Ruminy P, Maingonnat C, Marchand V, Lanic H, Penther D, Bastard C, Tilly H, Jardin F.
Dubois S, et al. Among authors: lanic h.
Oncotarget. 2015 Jun 30;6(18):16712-24. doi: 10.18632/oncotarget.3154.
Oncotarget. 2015.
PMID: 25762637
Free PMC article.